02181.HK
Mabpharm Limited
HKSE · Healthcare · Biotechnology · CN
HKD 0.45
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 898.1M | 629.4M | 258.2M | 87.2M | 55.9M |
| Cost of Revenue | 129.0M | 107.8M | 38.8M | 11.9M | 15.4M |
| Gross Profit | 769.1M | 521.5M | 219.4M | 75.2M | 40.5M |
| Operating Expenses | |||||
| R&D Expense | 127.6M | 49.3M | 75.2M | 123.2M | 147.9M |
| SG&A Expense | 756.4M | 467.6M | 180.5M | 69.9M | 50.2M |
| General & Admin Expense | 80.3M | — | 28.9M | 21.0M | 22.0M |
| Selling & Marketing Expense | 314.8M | — | 151.6M | 48.9M | 28.2M |
| Other Expenses | — | — | 83.4M | 84.1M | 68.7M |
| Total Operating Expenses | 884.0M | 516.9M | 339.1M | 277.2M | 266.8M |
| Cost and Expenses | 1.0B | 624.7M | 377.9M | 289.1M | 282.2M |
| Operating Income (EBIT) | (114.9M) | 4.7M | (119.7M) | (202.0M) | (226.3M) |
| Non-Operating | |||||
| Interest Income | 1.0M | 421.8K | 513.0K | 151.0K | 382.0K |
| Interest Expense | 21.2M | 10.5M | 10.6M | 9.6M | 7.2M |
| Net Interest Income | (20.8M) | (10.1M) | (10.0M) | (9.4M) | (6.8M) |
| Other Non-Op Income/Expense | (8.9M) | (626.4K) | (8.3M) | (7.4M) | 15.4M |
| Non-Operating Income (excl Interest) | — | — | — | (2.2M) | 4.4M |
| EBT (Pre-Tax Income) | (123.8M) | 4.1M | (127.9M) | (209.4M) | (210.8M) |
| Income Tax Expense | (52.1M) | (51.6M) | — | — | (199.0K) |
| Bottom Line | |||||
| Net Income | (71.7M) | 55.7M | (127.9M) | (209.4M) | (210.6M) |
| Earnings from Cont. Ops | (71.7M) | 55.7M | (127.9M) | (209.4M) | (210.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (71.7M) | 55.7M | (127.9M) | (209.4M) | (210.8M) |
| Per Share | |||||
| Basic EPS | (HK$0.02) | HK$0.01 | (HK$0.03) | (HK$0.05) | (HK$0.05) |
| Diluted EPS | (HK$0.02) | HK$0.01 | (HK$0.03) | (HK$0.05) | (HK$0.05) |
| Revenue Per Share | HK$0.22 | HK$0.15 | HK$0.06 | HK$0.02 | HK$0.01 |
| Shares | |||||
| Basic Shares Outstanding | 4.1B | 4.1B | 4.1B | 4.1B | 4.1B |
| Diluted Shares Outstanding | 4.1B | 4.1B | 4.1B | 4.1B | 4.1B |
| Profitability Metrics | |||||
| EBITDA | (6.4M) | 62.9M | (67.8M) | (139.1M) | (152.1M) |
| D&A | 108.5M | 58.2M | 51.9M | 60.7M | 51.5M |
| EBIT | (114.9M) | 4.7M | (119.7M) | (199.8M) | (203.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025